We predict that strategies that enhance VISTA-regulated inhibitory signaling will dampen IL-23-mediated inflammatory axis and benefit the treatment of not only human psoriasis, but also other inflammatory diseases driven by IL-23. The gene discussed is VSIR; the disease is psoriasis.